Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Clover Plans to Add Adolescents to List of Groups Approved for COVID-19 Vaccine

publication date: Aug 25, 2022

Shanghai Clover Biopharma reported its COVID-19 vaccine candidate met its primary endpoint in a global Phase II/III trial in adolescents (12 to 17 years). Following treatment with SCB-2019 (CpG 1018/Alum), adolescent trial participants experienced 2-fold higher neutralizing antibody titers compared to young adults (18 to 25 years). Previously, SCB-2019 proved to be highly protective against COVID-19 among young adults. Clover will seek approval in China, the EU and WHO for use of the vaccine across age groups as a COVID-19 vaccine and a universal COVID-19 booster vaccine. More details....

Stock Symbol: (HK: 02197)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital